Queen Mary University of London. "New injection could help millions with high blood pressure." ScienceDaily. ScienceDaily, 28 May 2025. <www.sciencedaily.com / releases / 2025 / 05 / 250528131544 ...

Roche’s Perjeta (pertuzumab)-based regimen has demonstrated sustained survival benefits in patients with early-stage breast cancer, according to new results from a long-term study of the drug. The ...

Roche's Perjeta, Herceptin and chemotherapy regimen cut the risk of death by 17% in patients with early-stage HER2-positive breast cancer over 10 years.

Key Takeaways The APHINITY study confirmed significant overall survival benefits of a Perjeta-based regimen in HER2-positive early-stage breast cancer, especially for lymph node-positive patients. Ten ...

Treatment with Herceptin (trastuzumab) and Perjeta (pertuzumab) with endocrine therapy but without chemotherapy has been shown to potentially be an effective treatment for patients with HER2-positive ...

The National Agency for Food and Drug Administration Control (NAFDAC), has alerted healthcare providers and the public of a report of counterfeit Perjeta units being in circulation in Nigeria.

Injection site reactions occur when a person’s immune system reacts to a vaccine injection. Often, this does not involve an allergic reaction, which is an immune response to a certain trigger ...

A version of this article appears in print on Nov. 20, 2023, Section A, Page 20 of the New York edition with the headline: Proof That Safe-Injection Sites Are Safe for Neighbors, Too .

HLX11 (anti-HER2 domain II humanized monoclonal antibody injection) is a biosimilar candidate of pertuzumab and is independently developed by Henlius.

PNG, short for Portable Network Graphics, is a popular and high-quality graphic file format. The PNG format is lossless and supports transparency.

Perjeta, in combination with trastuzumab and chemotherapy was previously authorized in 2018 as an adjuvant treatment of patients with HER2-positive early breast cancer with lymph node positive and ...